The prognostic value of positron emission tomography performed after two courses (INTERIM-PET) of standard therapy on treatment outcome in early stage Hodgkin lymphoma: A multicentric study by the fondazione italiana linfomi (FIL)

American Journal of Hematology

Volumn 90, Issue 6, 2015, Pages 499-503

  Rigacci, Luigi ^a   Puccini, Benedetta ^a   Zinzani, Pier Luigi ^b   Biggi, Alberto ^c   Castagnoli, Antonio ^d   Merli, Francesco ^e   Balzarotti, Monica ^f   Stelitano, Caterina ^g   Spina, Michele ^h   Vitolo, Umberto ⁱ   Stefoni, Vittorio ^b   Levis, Alessandro ^j   Gotti, Manuel ^k   Rosaria, Sancetta ^l   Maria, Stefani Piero ^m   Bosi, Alberto ^a   Gallamini, Andrea ^c  

^a CAREGGI UNIVERSITY HOSPITAL   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

^c S CROCE E CARLE HOSPITAL   (Italy)

^d Department of Rheumatology Nuovo Ospedale S Stefano   (Italy)

^e S MARIA NUOVA HOSPITAL   (Italy)

^f HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^g BIANCHI MELACRINO MORELLI HOSPITAL   (Italy)

^h CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

ⁱ UNIVERSITY OF TURIN   (Italy)

^j C Arrigo Children's Hospital   (Italy)

^k UNIVERSITY OF PAVIA   (Italy)

^l OSPEDALE DELL'ANGELO   (Italy)

^m OSPEDALE CA FONCELLO   (Italy)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BLEOMYCIN; DACARBAZINE; DOXORUBICIN; VINBLASTINE;

ADULT; ARTICLE; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CANCER REGRESSION; CANCER STAGING; DIAGNOSTIC TEST ACCURACY STUDY; DRUG TREATMENT FAILURE; FAILURE FREE SURVIVAL; FEMALE; FOLLOW UP; HODGKIN DISEASE; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; POSITRON EMISSION TOMOGRAPHY; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RADIATION FIELD; RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; ADOLESCENT; AGED; CLINICAL TRIAL; DISEASE FREE SURVIVAL; MIDDLE AGED; MULTICENTER STUDY; PATHOLOGY; RADIOGRAPHY; SURVIVAL RATE;

ADOLESCENT; ADULT; AGED; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; HODGKIN DISEASE; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; POSITRON-EMISSION TOMOGRAPHY; PREDICTIVE VALUE OF TESTS; SURVIVAL RATE;

EID: 84929502919     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.23994     Document Type: Article

References (32)

1. Linch DC, Gosden RG, Tulandi T, et al. Hodgkin's lymphoma: Choice of therapy and late complications. Hematology (Am Soc Hematol Educ Program) 2000;205-221.
2. Donaldson SS, Hancock SL, Hoppe RT. Tha janeway lecture. Hodgkin's disease-Finding the balance between cure and late effects. Cancer J Sci Am. 1999;5:325-333.
3. Crowther D, Lister TA. The cotswolds report on the investigation and staging of hodgkin's disease. Br J Cancer 1990;62:551-552.
4. Vinnicombe SJ, Reznek RH. Computerised tomography in the staging of hodgkin's disease and non-hodgkin's lymphoma. Eur J Nucl Med Mol Imaging 2003;30:S42-S55.
5. Menzel C, Dobert N, Mitrou P, et al. Positron emission tomography for the staging of hodgkin's lymphoma-Increasing the body of evidence in favor of the method. Acta Oncol 2002;41:430-436.
6. Naumann R, Beuthien-Baumann B, Reiss A, et al. Substantial impact of FDG PET imaging on the therapy decision in patients with early-stage hodgkin's lymphoma. Br J Cancer 2004;90:620-625.
7. Partridge S, Timothy A, O'Doherty MJ, et al. 2-Fluorine-18-fluoro-2-deoxy-D glucose positron emission tomography in the pretreatment staging of hodgkin's disease: Influence on patient management in a single institution. Ann Oncol 2000;11:1273-1279.
8. Delbeke D, Martin WH, Morgan DS, et al. 2-Deoxy-2-[F-18]fluoro-D-glucose imaging with positron emission tomography for initial staging of hodgkin's disease and lymphoma. Mol Imaging Biol 2002;4:105-114.
9. Gallamini A, Rigacci L, Merli F, et al. The predictive value of positron emission tomography scanning performed after two courses of standard therapy on treatment outcome in advanced stage hodgkin's disease. Haematologica 2006;91:475-481.
10. Gallamini A, Hutchings M, Rigacci L, et al. Early interim 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage hodgkin's lymphoma: A report from a joint Italian-danish study. J Clin Oncol. 2007;25:3746-3752.
11. Hutchings M, Loft A, Hansen M, et al. FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in hodgkin lymphoma. Blood 2006;107:52-59.
12. Gallamini A, Fiore F, Sorasio R, Meignan M. Interim positron emission tomography scan in hodgkin lymphoma: Definitions, interpretation rules and clinical validation. Leuk Lymph 2009;50:1761-1764.
13. Dann EJ, Bar-Shalom R, Tamir A, Epelbaum R, Avivi I, Ben-Shachar M, Gaitini D, Rowe JM. A functional dynamic scoring model to elucidate the significance of post-induction interim fluorine-18-fluorodeoxyglucose positron emission tomography findings in patients with hodgkin's lymphoma. Haematologica. 2010;95:1198-1206.
14. Radford J. Treatment for early-stage hodgkin lymphoma: Has radiotherapy had its days? J Clin Oncol 2012;30:3783-3785.
15. Lister TA, Crowther D, Sutcliffe SB, et al. Report of a committee convened to discuss the evaluation and staging of patients with hodgkin's disease: Cotswolds meeting. J Clin Oncol 1989:1630-1636.
16. Cheson BD, Horning SJ, Coiffier B, et al. Report of an international workshop to standardize response criteria for non-hodgkin's lymphomas. NCI sponsored international working group. J Clin Oncol 1999;17:1244.
17. Meignan M, Gallamini A, Itti E, et al. Reporto on the third international workshop on interim positron emission tomography in lymphoma held in menton, france, 26-27 september 2011 and menton 2011 consensus. Leuk Lymphoma 2012;53:1876-1881.
18. SPSS for Windows, Version 8.0, Spss Inc., U.S.A. 1998
19. Engert A, Plutshow A, Eich HT, et al. Reduced treatment intensity in patients with early-stage Hodgkin's lymphoma. N Engl J Med 2010;363:640-652.
20. Eich HT, Diehl V, Gorgen H, et al. Intensified chemotherapy and dose-reduced involved-field radiotherapy in patients with early unfavorable Hodgkin's lymphoma: final analysis of the German Hodgkin Study Group HD11 trial. J Clin Oncol 2010;28:4199-4206.
21. vonTresckow B, Plutschow A, Fuchs M, et al. Dose-intensification in early unfavourable hodgkin's lymphoma: Final analysis of the german hodgkin study group HD14 trial. J Clin Oncol 2012;30:907-913.
22. Terasawa T, Nagai H. Current clinical evidence on interim fluorine-18 fluorodeoxy glucose positron emission tomography for advanced-stage hodgkin lymphoma and diffuse large B-cell lymphoma to predict clinical outcome. Leuk Lymph 2009;50:1750-1752.
23. Barnes JA, LaCasce AS, Zukotynski K, et al. End of treatment but not interim PET scan predicts outcome in nonbulky limited-stage hodgkin's lymphoma. Ann Oncol 2011;22:910-915.
24. Zinzani PL, Rigacci L, Stefoni V, et al. Early interim 18-F-FDG PET in hodgkin's lymphoma: evaluation on 304 patents. Eur J Nucl Med Mol Imaging 2011;39:4-12.
25. Fludeoxyglucose F 18 PET scan-guided therapy or standard therapy in treating patients with previously untreated stagr I or II Hodgkin's lymphoma (EORTC/GELA/FIL). Availabe at: http://clinicaltrials.gov/ct2/show/NCT00433433. Accessed August 3, 2012
26. Biggi A, Gallamini A, Chauvie S, et al. International validation study for interim PET in ABVD-treated advanced-stage hodgkin lymphoma: Interpretation criteria and concordance rate among reviewers. J Nucl Med 2013;54:683-690.
27. Straus DJ, Johnson JL, LaCasce AS, et al. Doxorubicin, vinblastine, and gemcitabine (CALGB 50203) for stage I/II nonbulky hodgkin lymphoma: Pretreatment prognostic factors and interim-PET. Blood 2011;117:5314-5320.
28. Kostakoglu L, Schoder H, Johnson JL, et al. Interim [(18)F]fluorodeoxyglucose positron emission tomography imaging in stage I-II non-bulky hodgkin lymphoma: Would using combined positron emission tomkgraphy and computed tomography criteria better predict response than each test alone?. Leuk Lymph 2012;53:2143-2150.
29. Spaepen K, Stroobants S, Verhoef G, Mortelmans L. Positron emission tomography with [(18)F]FDG for therapy response monitoring in lymphoma patients. Eur J Nucl Med Mol Imaging 2003;30 (Suppl 1):S97-S105.
30. Filippi AR, Botticella A, Bellò M, et al. Interim positron emission tomography and clinical outcome in patients with early stage hodgkin lymphoma treated with combined modality therapy. Leuk Lymph 2013;54:1183-1187.
31. Radford J, Barrington S, Counsell N, et al. Involved field radiotherapy versus no further treatment in patients with clinical stages IA and IIA Hodgkin lymphoma and a 'negative' PET scan after 3 cycles ABVD: Results of the UK NCRI RAPID trial. Abstract 547; Annual Meeting of ASH. December, 10: 2012.
32. Evens AM. Role of PET in defining prognosis of Hodgkin lymphoma for early stage disease. Education Program ASH Meeting. December 6, 2014.